Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 9:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1057–1080 of 2,504 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Leukemia, Myelogenous, Acute Clear all
Terminated Phase 2 Interventional Results available

Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia

NCT01158885
View directory record Official record
Conditions
Minimal Residual Disease, Leukemia, Lymphoblastic, Acute, Leukemia, Myelogenous, Acute
Interventions
Clofarabine, Cytarabine intravenous, Methotrexate, Intrathecal (IT) Cytarabine
Drug
Lead sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Other
Eligibility
1 Year to 21 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Charlotte, North Carolina • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 26, 2021 · Synced Oct 19, 2026, 9:16 PM EDT
Completed Phase 2 Interventional

A Study of Active Immunotherapy With GRNVAC1 in Patients With Acute Myelogenous Leukemia (AML)

NCT00510133
View directory record Official record
Conditions
Acute Myelogenous Leukemia
Interventions
GRNVAC1
Biological
Lead sponsor
Asterias Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
6
States / cities
Atlanta, Georgia • Maywood, Illinois • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2019 · Synced Oct 19, 2026, 9:16 PM EDT
Terminated Phase 3 Interventional Results available

A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)

NCT04161885
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML), Cancer
Interventions
Venetoclax, Azacitidine, Best Supportive Care (BSC)
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
12 Years and older
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
43
States / cities
Scottsdale, Arizona • Tucson, Arizona • Little Rock, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 19, 2026, 9:16 PM EDT
Completed Phase 1 Interventional

Phase I Epigenetic Priming Using Decitabine With Induction Chemotherapy in AML

NCT00538876
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
decitabine
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 30, 2011 · Synced Oct 19, 2026, 9:16 PM EDT
Completed Phase 1Phase 2 Interventional

Busulfan, Antithymocyte Globulin, and Fludarabine Followed By a Donor Stem Cell Transplant in Treating Young Patients With Blood Disorders, Bone Marrow Disorders, Chronic Myelogenous Leukemia in First Chronic Phase, or Acute Myeloid Leukemia in First Remission

NCT00305708
View directory record Official record
Conditions
Congenital Amegakaryocytic Thrombocytopenia, Diamond-blackfan Anemia, Fanconi Anemia, Leukemia, Severe Congenital Neutropenia, Thrombocytopenia
Interventions
anti-thymocyte globulin, busulfan, fludarabine phosphate, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation, umbilical cord blood transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
University of California, San Francisco
Other
Eligibility
Up to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 12, 2012 · Synced Oct 19, 2026, 9:16 PM EDT
Active, not recruiting Phase 1 Interventional

Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in AML Patients

NCT03679650
View directory record Official record
Conditions
Acute Myelogenous Leukemia
Interventions
DC/AML fusion cells
Biological
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 19, 2026, 9:16 PM EDT
Completed Phase 1 Interventional

Cord Blood Expansion on Mesenchymal Stem Cells

NCT00498316
View directory record Official record
Conditions
Myelodysplastic Syndrome, Leukemia
Interventions
Cord Blood Infusion, Busulfan, Fludarabine, Rituximab, ATG, Cyclophosphamide, Clofarabine, Total Body Irradiation (TBI), Melphalan, Tacrolimus, Mycophenolate Mofetil, G-CSF
Procedure · Drug · Other + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
1 Year to 80 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 28, 2020 · Synced Oct 19, 2026, 9:16 PM EDT
Completed Phase 2 Interventional Results available

Dociparstat Sodium (CX-01) Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia

NCT02873338
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Dociparstat sodium, Idarubicin, Cytarabine
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
60 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
23
States / cities
La Jolla, California • Denver, Colorado • Washington D.C., District of Columbia + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Oct 19, 2026, 9:16 PM EDT
Completed Phase 1 Interventional

Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands

NCT02203825
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome, Multiple Myeloma
Interventions
CM-CS1 T-cell infusion
Biological
Lead sponsor
Celyad Oncology SA
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 1, 2018 · Synced Oct 19, 2026, 9:16 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia

NCT02257138
View directory record Official record
Conditions
Blasts More Than 20 Percent of Bone Marrow Nucleated Cells, Blasts More Than 20 Percent of Peripheral Blood White Cells, Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Decitabine, Laboratory Biomarker Analysis, Ruxolitinib Phosphate
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 8, 2025 · Synced Oct 19, 2026, 9:16 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

NCT01522976
View directory record Official record
Conditions
Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts, Myelodysplastic Syndrome With Excess Blasts-1, Myelodysplastic Syndrome/Acute Myeloid Leukemia
Interventions
Azacitidine, Laboratory Biomarker Analysis, Lenalidomide, Vorinostat
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2027
U.S. locations
280
States / cities
Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 217 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 19, 2026, 9:16 PM EDT
Completed Phase 1 Interventional

Melphalan in Patients With Neoplastic Meningitis

NCT00002750
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Leukemia, Lymphoma, Ovarian Cancer
Interventions
melphalan
Drug
Lead sponsor
Duke University
Other
Eligibility
3 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2001
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 20, 2013 · Synced Oct 19, 2026, 9:16 PM EDT
Completed Phase 2 Interventional Results available

Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies

NCT04191187
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Biphenotypic Acute Leukemia, Undifferentiated Leukemia, Prolymphocytic Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia, Myeloproliferative Neoplasm, Relapsed Large Cell Lymphoma, Mantle Cell Lymphoma, Hodgkin Lymphoma, Burkitt Lymphoma, Relapsed T-Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, Relapsed Small Lymphocytic Lymphoma, Relapsed Marginal B-cell Lymphoma, Relapsed Follicular Lymphoma, Lymphoplasmacytic Lymphoma
Interventions
Fludarabine, Melphalan, Total Body Irradiation
Drug · Radiation
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 19, 2026, 9:16 PM EDT
Recruiting Phase 1 Interventional

CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia

NCT05672147
View directory record Official record
Conditions
Acute Myeloid Leukemia, Recurrent Adult Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
Interventions
Anti-CD33 CAR T-cells, Lymphodepletion Therapy
Biological · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 19, 2026, 9:16 PM EDT
Completed No phase listed Observational

Feasibility and Safety of Functional Performance Testing in Patients Undergoing Hematopoietic Cell Transplantation

NCT02598752
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome, Hematological Malignancy, Leukemia, Lymphoma, Myeloma
Interventions
Symptom-limited cardiopulmonary exercise test (CPET), Resting assessment of cardiac function by echocardiography, Post-exercise assessment of cardiac function by echocardiography, Pulmonary function, Patient-reported outcomes questionnaire
Other · Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 16, 2020 · Synced Oct 19, 2026, 9:16 PM EDT
Completed Phase 1Phase 2 Interventional

Arsenic Trioxide in Combination With Cytarabine in Patients With High-risk MDS and Poor-prognosis AML

NCT00195104
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
Arsenic Trioxide (Tricenox), Cytarabine
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 19, 2026, 9:16 PM EDT
Terminated No phase listed Observational

Effectiveness of Protected Environment Rooms for AML and MDS

NCT00443300
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Interventions
Not listed
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
60 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 2, 2012 · Synced Oct 19, 2026, 9:16 PM EDT
Completed Phase 1 Interventional

Combination Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Leukemia

NCT00462787
View directory record Official record
Conditions
Leukemia
Interventions
filgrastim, clofarabine, dexamethasone, thiotepa, topotecan hydrochloride, vinorelbine tartrate
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 28 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 14, 2013 · Synced Oct 19, 2026, 9:16 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD)

NCT03699384
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML), Minimal Residual Disease
Interventions
Azacitidine, Avelumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 20, 2019 · Synced Oct 19, 2026, 9:16 PM EDT
Terminated Phase 2 Interventional Results available

Trial of Arsenic Trioxide With Ascorbic Acid in the Treatment of Adult Non-Acute Promyelocytic Leukemia (APL) Acute Myelogenous Leukemia

NCT00184054
View directory record Official record
Conditions
Acute Myelogenous Leukemia
Interventions
Arsenic Trioxide (ATO), Ascorbic Acid
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 25, 2014 · Synced Oct 19, 2026, 9:16 PM EDT
Completed Phase 1Phase 2 Interventional

Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome

NCT00004918
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia in Remission, Chronic Phase Chronic Myelogenous Leukemia, Previously Treated Myelodysplastic Syndromes, Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, Relapsing Chronic Myelogenous Leukemia
Interventions
PR1 leukemia peptide vaccine, Montanide ISA 51 VG, sargramostim, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
19 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 7, 2013 · Synced Oct 19, 2026, 9:16 PM EDT
Completed Phase 1 Interventional

Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma

NCT01943682
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Burkitt Lymphoma, Diffuse Large Cell Lymphoma, Gray Zone Lymphoma, Lymphoblastic Lymphoma, Anaplastic Large Cell Lymphoma, Hodgkin Lymphoma
Interventions
CPX-351
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
12 Months to 30 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 9, 2020 · Synced Oct 19, 2026, 9:16 PM EDT
Completed Phase 2 Interventional Results available

PF-04449913 For Patients With Acute Myeloid Leukemia at High Risk of Relapse After Donor Stem Cell Transplant

NCT01841333
View directory record Official record
Conditions
Adult Acute Myeloid Leukemia in Remission, Recurrent Adult Acute Myeloid Leukemia
Interventions
PF-04449913
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
2
States / cities
Aurora, Colorado • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 25, 2022 · Synced Oct 19, 2026, 9:16 PM EDT
Completed Phase 2 Interventional Results available

Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow

NCT00003838
View directory record Official record
Conditions
Myeloproliferative Disorders, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia
Interventions
T-cell replete PBPC allograft, Methotrexate, Cyclosporine, G-CSF
Procedure · Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years to 80 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 19, 2026, 9:16 PM EDT